Navigation Links
New 'bouncer' molecule halts rheumatoid arthritis
Date:9/7/2011

CHICAGO -- Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons.

The Feinberg School team has identified this bouncer, a protein called P21, which prevents immune cells from launching into their destructive rampage through the cartilage and bone. When the scientists developed and injected an imitation of the protein into an animal model of rheumatoid arthritis, the disease process was halted.

"The bouncer molecule stopped the immune cells from going crazy," said lead author Harris Perlman, associate professor of rheumatology at Northwestern's Feinberg School. "Imagine destructive customers in a bar, and the bouncer says, 'You are going to behave!' That's P21. This discovery opens up a new avenue for future therapies, which are greatly needed for rheumatoid arthritis."

Previous research by the Feinberg team showed people with rheumatoid arthritis were low in P21, but the protein's role was unknown. The new study, which will be published in the journal Arthritis & Rheumatism, reveals the protein's vital role in keeping the immune cells in check.

Currently, there is no effective, nontoxic way to stop the hyperactive immune cells, Perlman said.

To develop the new approach, Perlman and his team tested five different parts, called peptides, of P21. He slipped each peptide into a "ghostlike" molecule that he injected into mice with a rheumatoid arthritis-like disease. The molecule secretly infiltrated the immune cells. After the seven-day trial, one of the tested peptides had calmed the overactive immune cells without toxic effects. Next, Perlman plans a 30-day study with the same peptide to monitor efficacy and toxicity over a longer period of time.

Existing treatments for rheumatoid arthritis include low-level chemotherapy and steroids. These are not always effective, however, and they are frequently accompanied by side effects. A newer class of therapy, which is sometimes used in combination with chemotherapy and steroids, is biologic response modifiers. These are antibodies or other proteins that reduce the inflammation produced by the hyperactive immune cells. These biologics don't work for everyone, though, and can be associated with side effects including the risk of infection.


'/>"/>

Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related biology news :

1. Unlocking the secret of the bladders bouncers
2. Small molecules shed light on cancer therapies
3. Regrowing blood vessels with a potent molecule
4. UCLA scientists complete first mapping of molecule found in human embryonic stem cells
5. Molecules light up Alzheimers roots
6. Newly discovered molecule essential to resetting body clocks
7. Supramolecules get time to shine
8. Crucial role for molecule in muscle development
9. Researchers decipher protein structure of key molecule in DNA transcription system
10. Treatment approach to human Usher syndrome: Small molecules ignore stop signals
11. Scientists a step closer to understanding natural antifreeze molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... India , Dec. 8, 2016 Market Research Future ... Service Market. The global Mobile Biometric Security and Service Market is ... 2016 to 2022. Market Highlights: ... , , Mobile ... pace due to the increasing need of authentication and security from ...
(Date:12/7/2016)... December 7, 2016 According to a new market research ... Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region - ... grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, ... Continue Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 2017 BD (Becton, Dickinson and Company) (NYSE: ... will host a live webcast of its Annual Meeting of Shareholders ... The webcast can be accessed from the BD corporate website ... January 31, 2017. ... About BD BD is a global medical technology company ...
(Date:1/18/2017)... CAMBRIDGE, Mass. , Jan. 18, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal ... San Francisco . Napabucasin is ... pathways by targeting STAT3. i Cancer stem cells ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm ... its continued commitment to the advancement of the clinical trials segment. Hosted in ... to clinical trial planning and management. , As executive talent specialists in ...
(Date:1/18/2017)... Frederick, Maryland (PRWEB) , ... January 18, 2017 ... ... of two new federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of ... Innovation in Manufacturing Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the ...
Breaking Biology Technology: